Lenalidomide maintenance for diffuse large ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Author(s) :
Thieblemont, Catherine [Auteur]
Hôpital Saint-Louis
Howlett, S. [Auteur]
Casasnovas, R. O. [Auteur]
Mounier, N. [Auteur]
Perrot, A. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Fruchart, C. [Auteur]
Daguindau, N. [Auteur]
Van Eygen, K. [Auteur]
Obéric, L. [Auteur]
Bouabdallah, R. [Auteur]
Pica, G. M. [Auteur]
Nicolas-Virezelier, E. [Auteur]
Abraham, J. [Auteur]
Fitoussi, O. [Auteur]
Snauwaert, S. [Auteur]
Eisenmann, J. C. [Auteur]
Lionne-Huyghe, P. [Auteur]
Bron, D. [Auteur]
Tricot, S. [Auteur]
Deeren, D. [Auteur]
Gonzalez, H. [Auteur]
Costello, R. [Auteur]
Le Du, K. [Auteur]
Da Silva, M. G. [Auteur]
Grosicki, S. [Auteur]
Trotman, J. [Auteur]
Catalano, J. [Auteur]
Caballero, D. [Auteur]
Greil, R. [Auteur]
Cohen, A. M. [Auteur]
Gaulard, P. [Auteur]
Roulin, L. [Auteur]
Takeshita, K. [Auteur]
Casadebaig, M. L. [Auteur]
Tilly, H. [Auteur]
Coiffier, B. [Auteur]
Hôpital Saint-Louis
Howlett, S. [Auteur]
Casasnovas, R. O. [Auteur]
Mounier, N. [Auteur]
Perrot, A. [Auteur]
Morschhauser, Franck [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Fruchart, C. [Auteur]
Daguindau, N. [Auteur]
Van Eygen, K. [Auteur]
Obéric, L. [Auteur]
Bouabdallah, R. [Auteur]
Pica, G. M. [Auteur]
Nicolas-Virezelier, E. [Auteur]
Abraham, J. [Auteur]
Fitoussi, O. [Auteur]
Snauwaert, S. [Auteur]
Eisenmann, J. C. [Auteur]
Lionne-Huyghe, P. [Auteur]
Bron, D. [Auteur]
Tricot, S. [Auteur]
Deeren, D. [Auteur]
Gonzalez, H. [Auteur]
Costello, R. [Auteur]
Le Du, K. [Auteur]
Da Silva, M. G. [Auteur]
Grosicki, S. [Auteur]
Trotman, J. [Auteur]
Catalano, J. [Auteur]
Caballero, D. [Auteur]
Greil, R. [Auteur]
Cohen, A. M. [Auteur]
Gaulard, P. [Auteur]
Roulin, L. [Auteur]
Takeshita, K. [Auteur]
Casadebaig, M. L. [Auteur]
Tilly, H. [Auteur]
Coiffier, B. [Auteur]
Journal title :
British Journal of Haematology
Abbreviated title :
Br. J. Haematol.
Volume number :
189
Pages :
84-96
Publisher :
Wiley
Publication date :
2019-11-16
ISSN :
1365-2141
Keyword(s) :
therapy
quality of life
non-Hodgkin lymphoma
quality of life
non-Hodgkin lymphoma
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. ...
Show more >Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. This subpopulation analysis assessed the impact of lenalidomide maintenance and treatment-emergent adverse events (TEAEs) on health-related quality of life (HRQOL). Global health status (GHS), and physical functioning and fatigue subscales were evaluated in patients who completed the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire-C30 v3.0. The impact of TEAEs classified post hoc as subjective (patients can feel) or observable (only measurable by physicians) on dose reductions and discontinuations was assessed. Among 457 patients (lenalidomide, n = 229; placebo, n = 228), mean (standard deviation) GHS was similar between treatment arms [68·2 (20·7) Versus 72·0 (17·8)] at randomisation and remained similar during maintenance. Patients receiving lenalidomide experienced no meaningful changes in GHS, physical functioning, or fatigue. Observable TEAEs were more common (81·1% Versus 66·3%) and more likely to lead to dose reductions, than subjective TEAEs in both arms. PFS was superior in the lenalidomide arm regardless of dose reduction. Lenalidomide maintenance prolonged PFS and did not negatively impact HRQOL in patients with DLBCL despite TEAEs being more common, when compared with placebo.Show less >
Show more >Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. This subpopulation analysis assessed the impact of lenalidomide maintenance and treatment-emergent adverse events (TEAEs) on health-related quality of life (HRQOL). Global health status (GHS), and physical functioning and fatigue subscales were evaluated in patients who completed the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire-C30 v3.0. The impact of TEAEs classified post hoc as subjective (patients can feel) or observable (only measurable by physicians) on dose reductions and discontinuations was assessed. Among 457 patients (lenalidomide, n = 229; placebo, n = 228), mean (standard deviation) GHS was similar between treatment arms [68·2 (20·7) Versus 72·0 (17·8)] at randomisation and remained similar during maintenance. Patients receiving lenalidomide experienced no meaningful changes in GHS, physical functioning, or fatigue. Observable TEAEs were more common (81·1% Versus 66·3%) and more likely to lead to dose reductions, than subjective TEAEs in both arms. PFS was superior in the lenalidomide arm regardless of dose reduction. Lenalidomide maintenance prolonged PFS and did not negatively impact HRQOL in patients with DLBCL despite TEAEs being more common, when compared with placebo.Show less >
Language :
Anglais
Audience :
Internationale
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Submission date :
2023-05-25T03:47:44Z
2023-09-27T08:46:06Z
2023-09-27T08:46:06Z
Files
- Br J Haematol - 2019 - Thieblemont.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 3.0 United States